Jacques Touchon

Summary

Country: France

Publications

  1. ncbi Prevention trials in Alzheimer disease: one step forward?
    J Touchon
    Neurology Service, Guy de Chauliac Hospital, Montpellier, France
    Neurology 67:S21-2. 2006
  2. ncbi Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology
    Jacques Touchon
    CHU, INSERM 361, Montpellier, France
    Curr Med Res Opin 22:49-59. 2006
  3. ncbi Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease
    Emilie Mas
    Department of Biochemistry, Lapeyronie Hospital, Montpellier, France
    Dement Geriatr Cogn Disord 21:198-204. 2006
  4. ncbi [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]
    Anne-Sophie Rigaud
    , Service du Pr F. Forette, , Paris
    Presse Med 32:1649-54. 2003
  5. ncbi Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1317-27. 2005
  6. ncbi Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Swindon, UK
    Curr Med Res Opin 22:483-94. 2006
  7. ncbi Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment
    Karim Bennys
    Department of Neurology, University Hospital of Montpellier, France
    J Clin Neurophysiol 24:405-12. 2007
  8. ncbi [Mild cognitive impairment]
    Jacques Touchon
    Service de Neurologie, CM2R du Languedoc Roussillon, Inserm E 361, CHU, Montpellier Cedex 05
    Presse Med 36:1464-8. 2007
  9. ncbi Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
    J Neurol 253:1154-9. 2006
  10. ncbi Mild extrapyramidal signs and functional impairment in ageing
    Marcus Richards
    MRC National Survey of Health and Development, University College London, UK
    Int J Geriatr Psychiatry 17:150-3. 2002

Collaborators

Detail Information

Publications14

  1. ncbi Prevention trials in Alzheimer disease: one step forward?
    J Touchon
    Neurology Service, Guy de Chauliac Hospital, Montpellier, France
    Neurology 67:S21-2. 2006
    ..A critical concern is the benefit and relative risk of giving a treatment to non-demented patients or to asymptomatic subjects. Some trials are under way and will perhaps move the field of prevention of dementia one big step forward...
  2. ncbi Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology
    Jacques Touchon
    CHU, INSERM 361, Montpellier, France
    Curr Med Res Opin 22:49-59. 2006
    ..This retrospective analysis investigated whether AD patients with and without symptoms suggesting concomitant Lewy body pathology demonstrated different responses to therapy...
  3. ncbi Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease
    Emilie Mas
    Department of Biochemistry, Lapeyronie Hospital, Montpellier, France
    Dement Geriatr Cogn Disord 21:198-204. 2006
    ..Our study strongly supports the hypothesis of an impairment of lipophilic antioxidant delivery to neuronal cells in AD leading to a tissular antioxidant deficiency which could facilitate oxidative stress...
  4. ncbi [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]
    Anne-Sophie Rigaud
    , Service du Pr F. Forette, , Paris
    Presse Med 32:1649-54. 2003
    ..CONCLUSION: Oestro-progestagen treatment did not provide further improvement when combined with rivastigmine during mild to moderately severe Alzheimer's disease...
  5. ncbi Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1317-27. 2005
    ....
  6. ncbi Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Swindon, UK
    Curr Med Res Opin 22:483-94. 2006
    ..This retrospective analysis investigated whether younger and older patients showed differential tolerability and efficacy responses to cholinesterase inhibitor treatment...
  7. ncbi Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment
    Karim Bennys
    Department of Neurology, University Hospital of Montpellier, France
    J Clin Neurophysiol 24:405-12. 2007
    ..The abnormalities of N2 and P3 components may be linked, in AD and MCI, to an alteration of automatic and controlled attention processing...
  8. ncbi [Mild cognitive impairment]
    Jacques Touchon
    Service de Neurologie, CM2R du Languedoc Roussillon, Inserm E 361, CHU, Montpellier Cedex 05
    Presse Med 36:1464-8. 2007
    ..Biological and radiological markers will provide greater and more systematic support for diagnosis in the near future, particularly for early detection of Alzheimer's disease...
  9. ncbi Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
    J Neurol 253:1154-9. 2006
    ....
  10. ncbi Mild extrapyramidal signs and functional impairment in ageing
    Marcus Richards
    MRC National Survey of Health and Development, University College London, UK
    Int J Geriatr Psychiatry 17:150-3. 2002
    ..Little is known about the clinical significance of mild extrapyramidal signs (EPS) in elderly individuals. We investigated whether EPS are associated with functional impairment in older people with cognitive decline...
  11. ncbi Mild cognitive impairment: a nosological entity?
    Thierry Voisin
    Department of Internal Medicine and Clinical Gerontology, Acute Unit for Alzheimer s Patients, Toulouse University, Toulouse, France
    Curr Opin Neurol 16:S43-5. 2003
    ..Future research should be focussed on redefining the criteria of the mild cognitive impairment entity. This could enable the better development of appropriate therapeutic interventions...
  12. ncbi Text structure and content modulate the recall of patients with dementia of the Alzheimer's type
    Marie Christine Gely-Nargeot
    Laboratoire de Psychologie Expérimentale et Cognitive, Université Montpellier III, Canada
    Brain Cogn 48:371-5. 2002
    ..Results are discussed with reference to the influence of text structure and the situation model on text recall...
  13. ncbi Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease
    François Torreilles
    CNRS UMR 5094, Institut de Biotechnologie et Pharmacologie, UFR Pharmacie, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France
    Prog Neurobiol 66:191-203. 2002
    ..The present review analyzes the main results of intrathecal content analyses in light of pathogenic theories proposed to explain the damage associated with AD and observed in the brain of patients by postmortem examination...
  14. ncbi [Prototypic value of semantic intrusion errors in Alzheimer's disease]
    Marianne Canolle
    Hopital Corentin Celton, Issy les Moulineaux, France
    Psychol Neuropsychiatr Vieil 6:67-79. 2008
    ..In conclusion, the qualitative analysis of the prototypic value of intrusion errors in Alzheimers opens up new clinical and methodological considerations...